AU2021903239A0 - Agents and methods for therapy and prophylaxis - Google Patents

Agents and methods for therapy and prophylaxis

Info

Publication number
AU2021903239A0
AU2021903239A0 AU2021903239A AU2021903239A AU2021903239A0 AU 2021903239 A0 AU2021903239 A0 AU 2021903239A0 AU 2021903239 A AU2021903239 A AU 2021903239A AU 2021903239 A AU2021903239 A AU 2021903239A AU 2021903239 A0 AU2021903239 A0 AU 2021903239A0
Authority
AU
Australia
Prior art keywords
prophylaxis
therapy
agents
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021903239A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viralok Therapeutics Pty Ltd
Original Assignee
Viralok Therapeutics Pty Ltd
Filing date
Publication date
Application filed by Viralok Therapeutics Pty Ltd filed Critical Viralok Therapeutics Pty Ltd
Publication of AU2021903239A0 publication Critical patent/AU2021903239A0/en
Priority to PCT/AU2022/050089 priority Critical patent/WO2022170396A1/en
Pending legal-status Critical Current

Links

AU2021903239A 2021-02-12 2021-10-08 Agents and methods for therapy and prophylaxis Pending AU2021903239A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/AU2022/050089 WO2022170396A1 (en) 2021-02-12 2022-02-11 Agents and methods for therapy and prophylaxis

Publications (1)

Publication Number Publication Date
AU2021903239A0 true AU2021903239A0 (en) 2021-10-21

Family

ID=

Similar Documents

Publication Publication Date Title
EP3920923A4 (en) Therapeutic agents and methods of treatment
EP4136254A4 (en) Ace2-targeted compositions and methods for treating covid-19
EP3931336A4 (en) Compositions and methods for treating laminopathies
EP4096675A4 (en) Compositions and methods for treating long covid
EP3938514A4 (en) Compounds and methods for reducing kcnt1 expression
EP4117662A4 (en) Methods for treating neutropenia
EP4117655A4 (en) Treatment methods
EP4090369A4 (en) Pericyte-sparing therapy
EP4017490A4 (en) Compounds and methods for treating oxalate-related diseases
EP3999092A4 (en) Combination cancer therapy agents and methods
EP4013401A4 (en) Articles and methods for administration of therapeutic agents
EP3965799A4 (en) Compositions and synergistic methods for treating infections
AU2021903239A0 (en) Agents and methods for therapy and prophylaxis
AU2021900345A0 (en) Agents and methods for therapy and prophylaxis
EP4175978A4 (en) Compositions and methods for treating crp-mediated diseases
GB202217355D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
EP4164619A4 (en) Treatment methods and formulations
EP4103192A4 (en) Compositions and methods for treating coronavirus infections
EP3999065A4 (en) Therapeutic compositions and methods for treating cancers
EP4104861A4 (en) Therapeutic agent for tauopathies
EP4003381A4 (en) Compositions and methods for treating skin infections and other diseases
EP3999076A4 (en) Compositions and methods for treating skin conditions
EP3946302A4 (en) Methods and compositions for treating pain
EP3996752A4 (en) Compositions and methods for treating peroxisomal biogenesis disorders
AU2020901854A0 (en) Therapeutic methods and agents